Form 4: ResMed Director Peter Farrell Acquires 536 RSUs

ResMed Inc. Director Peter C. Farrell reported the acquisition of 536 Restricted Stock Units, vesting by November 2026, under a pre-planned transaction.

Summary

• Peter C. Farrell, a Director and Chairman emeritus of ResMed Inc., acquired 536 shares of ResMed Common Stock.
• The acquisition occurred on November 20, 2025, at a price of $0 per share.
• These shares represent Restricted Stock Units (RSUs) which vest in full on the earlier of November 11, 2026, or the annual meeting of stockholders in the year following the grant date.
• Following this transaction, Mr. Farrell beneficially owns 70,773 shares directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-planned purchase or sale of equity securities.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine insider compensation report. The acquisition of RSUs by a director is generally seen as a positive sign of alignment with shareholder interests, but it is not a significant market-moving event.

Positives

• Director Peter C. Farrell's acquisition of 536 Restricted Stock Units aligns his interests with shareholders.
• The transaction was pre-planned under a Rule 10b5-1(c) plan, indicating a structured and compliant approach to equity compensation.

Future Outlook

The filing indicates future vesting of Restricted Stock Units by November 11, 2026, or the annual meeting following the grant date, suggesting continued alignment of director interests with long-term company performance.

Industry Context

This is a routine insider transaction filing, common across all publicly traded companies, reflecting standard equity compensation practices for directors. It does not provide specific industry-related insights beyond the company's general operations.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) at a $0 price is a standard form of equity compensation for directors and executives across various industries, including medical devices.
• The use of a Rule 10b5-1(c) plan for such transactions is a common best practice for insiders to avoid accusations of trading on material non-public information.
• The vesting schedule (earlier of a specific date or annual meeting) is typical for director equity awards, designed to retain and incentivize long-term commitment.

Related Party Transactions

• Grant of 536 Restricted Stock Units to Peter C. Farrell, a Director and Chairman emeritus, as part of his compensation package.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns management's interests with long-term shareholder value.

Next Steps

• Vesting of the 536 Restricted Stock Units on the earlier of November 11, 2026, or the annual meeting of stockholders in the year following the grant date.

Key Dates

Recommendation

The Form 4 reports a routine grant of Restricted Stock Units to a director as part of their compensation package. This type of transaction is standard practice and does not indicate any significant operational or financial changes that would warrant a change in investment thesis. The director's continued equity ownership aligns their interests with shareholders, which is a generally positive but not market-moving factor. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

ResMed, RMD, Peter Farrell, Form 4, Insider Trading, Restricted Stock Units, RSUs, Director Compensation, Equity Grant, Beneficial Ownership